-
Development of Small Molecule Activators of Nurr1 as Potential Therapeutics for Parkinson's Disease
… side effects, including involuntary movements called dyskinesias. By enhancing survival of dopamine-producing … Nurr1 activation may boost dopamine levels without inducing dyskinesias. Next Steps for Development: We will continue …
-
Marc G. Caron, PhD
… at the dopamine D1 receptors can eliminate levodopa-induced dyskinesias. His proposed work is to develop a …
-
Angelika Richter, PhD
… on animal models of neurological disorders (dystonia, dyskinesias, Parkinson’s disease, tremor, epilepsy), …
-
Glenn T. Stebbins, PhD
… having participated in the development of the Unified Dyskinesia Rating Scale (UDysRS), serving on the steering …
-
Daniel Tarsy, MD
… for Parkinson’s disease, dystonia, tremor, and tardive dyskinesia. He established the stereotactic DBS program and …
-
Andrea Giuffrida, PhD
… and PPAR receptors in Parkinson’s disease, L-DOPA-induced dyskinesias, and psychomotor disorders. …